Physician profile
Christopher Lee Beene
NPI 1740476951
$4,448.93
in general payments reported to CMS, 2019-2025
35 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $756 · 2021: $928 · 2022: $741 · 2023: $461 · 2024: $486 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.07 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $732.01 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $519.46 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $486.88 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.35 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.59 | 2019-2024 | Xifaxan |
| Lilly USA, LLC | $196.84 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $192.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Mylan Specialty L.P. | $178.45 | 2019-2022 | |
| Pfizer INC. | $172.59 | 2019-2025 | |
| Allergan, INC. | $148.54 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $144.41 | 2025 | Austedo Xr, Ajovy, Uzedy |
| Eisai INC. | $135.52 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $135.35 | 2020-2025 | Airsupra |
| Antares Pharma, INC. | $120.76 | 2020-2024 | Xyosted, Tlando, Nocdurna |
| Sanofi-Aventis U.S. LLC | $107.24 | 2019-2022 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Beene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.